CN111184792B - 一种治疗膝骨关节炎的中药组合物 - Google Patents
一种治疗膝骨关节炎的中药组合物 Download PDFInfo
- Publication number
- CN111184792B CN111184792B CN202010096924.1A CN202010096924A CN111184792B CN 111184792 B CN111184792 B CN 111184792B CN 202010096924 A CN202010096924 A CN 202010096924A CN 111184792 B CN111184792 B CN 111184792B
- Authority
- CN
- China
- Prior art keywords
- parts
- osteoarthritis
- traditional chinese
- joint
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 58
- 208000003947 Knee Osteoarthritis Diseases 0.000 title claims abstract description 30
- 244000197580 Poria cocos Species 0.000 claims abstract description 24
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 20
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 20
- 241000218176 Corydalis Species 0.000 claims abstract description 20
- 244000171085 Polyporus umbellatus Species 0.000 claims abstract description 18
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 238000001914 filtration Methods 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 24
- 238000005728 strengthening Methods 0.000 abstract description 23
- 210000000952 spleen Anatomy 0.000 abstract description 20
- 230000036407 pain Effects 0.000 abstract description 18
- 208000002193 Pain Diseases 0.000 abstract description 17
- 208000004880 Polyuria Diseases 0.000 abstract description 10
- 230000035619 diuresis Effects 0.000 abstract description 10
- 230000008961 swelling Effects 0.000 abstract description 10
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 9
- 206010023232 Joint swelling Diseases 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract description 6
- 230000008407 joint function Effects 0.000 abstract description 6
- 208000006820 Arthralgia Diseases 0.000 abstract description 5
- 210000001503 joint Anatomy 0.000 abstract description 5
- 201000004595 synovitis Diseases 0.000 abstract description 4
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 206010042727 Swollen tongue Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 35
- 210000000845 cartilage Anatomy 0.000 description 19
- 210000000629 knee joint Anatomy 0.000 description 19
- 238000002156 mixing Methods 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 206010042674 Swelling Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 210000001188 articular cartilage Anatomy 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- 210000001258 synovial membrane Anatomy 0.000 description 7
- 241000972672 Phellodendron Species 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 241000241550 Cyathula Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 230000008409 synovial inflammation Effects 0.000 description 5
- 241000132012 Atractylodes Species 0.000 description 4
- 241000218691 Cupressaceae Species 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 235000001188 Peltandra virginica Nutrition 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 206010007710 Cartilage injury Diseases 0.000 description 3
- 241000903946 Clematidis Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000972673 Phellodendron amurense Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000382455 Angelica sinensis Species 0.000 description 2
- 235000003826 Artemisia Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 244000189799 Asimina triloba Species 0.000 description 2
- 235000006264 Asimina triloba Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000488974 Loranthus Species 0.000 description 2
- 241000222640 Polyporus Species 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 244000030166 artemisia Species 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 244000195896 dadap Species 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001254604 Angelica pubescens Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 241000195954 Lycopodium clavatum Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 241001369613 Stephania tetrandra Species 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000010731 swelling symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗骨关节炎的中药组合物及其制备方法。所述中药组合物由如下重量份的原料药制成:茯苓10‑20份、桂枝5‑15份、苍术2‑8份、黄柏2‑8份、防己2‑8份、猪苓2‑8份、骨碎补2‑8份、延胡索5‑15份、川牛膝3‑9份。本发明组合物具有健脾利湿、祛风清热和通络止痛的功能,临床适用于膝骨关节炎发作期风湿热痹者,症见关节肿胀疼痛,屈伸不利,甚者局部发热红肿,舌体胖大有齿痕,苔黄腻,脉弦数。用本发明组合物对膝骨关节炎兔进行干预,结果显示其能减轻骨关节炎兔关节肿胀、皮温升高等症状、改善关节功能,并降低关节内IL‑1β、TNFα、PGE2、NO的含量,减轻滑膜炎,延缓膝骨关节炎进展。临床观察显示该发明物对膝骨关节炎患者具有消肿止痛、改善关节功能的作用。
Description
技术领域
本发明涉及中药领域,具体地,涉及一种治疗骨关节炎的中药组合物。
背景技术
骨关节炎是以关节软骨退变为核心的累及骨质、滑膜、关节囊及关节其他结构的多方位、多层次、不同程度的慢性炎症。临床主要表现为关节疼痛、肿胀及功能受限,活动及负重后疼痛加剧,休息后减轻,并有晨僵和胶着现象,可分为有症状性(急性发作期) 和无症状性(又称放射学骨关节炎),特别的,发作期骨关节炎尤其严重影响患者的生存质量。对于骨关节炎尤其是发作期的治疗,目前尚缺乏有效的治疗方法,西医多采用非甾体类抗炎止痛药物为主,虽然可减轻患者疼痛症状,但可引起严重的肝、肾损害及上消化道出血等不良反应,且容易复发。因此,寻求安全有效的治疗方法仍然是研究者探索的问题。
研究证实,在骨关节炎发作期的症状中,疼痛、肿胀和屈伸不利与滑膜组织发生病变有关。关节炎滑膜病变可分为增生、炎症、纤维化等不同亚型,在关节炎早期存在更多的滑膜炎症,而在晚期观察到更多的是滑膜纤维化。越来越多的证据表明滑膜炎症在骨关节炎发病机制和进展中具有重要作用。因此,滑膜炎症逐渐成为骨关节炎发病机制及治疗研究的新目标。
中医药在骨关节炎的治疗中发挥着重要的作用,并且具有毒副作用小、价格便宜、疗效确切等优势,尤其对早期膝骨关节炎的治疗已越来越引起医学界的重视,已取得了初步成果。目前骨关节炎的中药多侧重于补益肝肾、强筋健骨、祛风止痛等,如:(1)CN102327380A公开了一种治疗膝关节骨性关节炎的中药组合物(公开日2012年1月25日),由熟地、补骨脂、淫羊藿、桑寄生、续断、狗脊、白芍、葛根、木瓜、牛膝、威灵仙、延胡索、杜仲、红花、当归和炙甘草组成,具有补肝肾、强筋骨、清热祛湿、补益气血、散寒通络之功效;(2)CN105770159A公开了一种治疗膝关节骨性关节炎的中药组合物(公开日2016年7月20日),由熟地、淫羊藿、川牛膝、肉苁蓉、黄芪、白芍、鸡血藤、没药、苍术、黄柏、茯苓、防风、独活等组成,具有滋肝补肾、祛风散寒、活血化瘀、祛湿止痛、舒经通络的功效;(3)CN103536777A公开了一种治疗膝关节骨性关节炎的中药组合物(公开日2014年1月29日),由威灵仙、桑寄生、神筋草、鸡血藤、川牛膝、木瓜、元胡份、防风、羌活、独活、秦艽、白术、云苓、黄柏、苍术、当归、桂枝、天麻、徐长卿、三七和甘草等组成,该组合物具有滋阴补肾、祛痰除风、化瘀止痛功效。
然而,发明者在近20年对膝骨关节炎的中医证候规律研究中发现,骨关节炎缓解期中医证候表现以肾虚为主,而发作期则以脾虚湿注为主。如上所述,目前的中医临床治疗药物多侧重补益肝肾,而具有健脾渗湿、清热利水、通络止痛功能,能明显缓解发作期骨关节炎关节肿胀、疼痛、功能受限症状,提高患者生存质量,延缓病情发展的有效药物未见。
发明者根据发作期骨关节炎的中医证候表现,考虑其病机为“脾虚水泛、湿注骨节、湿热痹阻”,主张健脾渗湿、清热利水、通络止痛治法,并根据临床经验自拟组方分别形成健脾祛湿方和本申请中药组合物。其中,健脾祛湿方由茯苓、猪苓、泽泻、炒白术、车前子、茵陈蒿、黄柏、党参、威灵仙、海桐皮共10味中药组成,临床治疗发作期膝骨关节炎疗效好,并已经授权中国发明专利(专利号ZL201310232103.6)。本申请中药组合物则由茯苓、桂枝、苍术、黄柏、防己、猪苓、骨碎补、延胡索、川牛膝共9味中药组成。与健脾祛湿方相比,本申请中药组合物药物组成不同(两方相同药物仅为猪苓、茯苓和黄柏),配伍也不同(健脾祛湿方以茯苓和炒白术为君药,本申请中药组合物以茯苓和桂枝为君药),且药味更少,处方量小(健脾祛湿方全方共101g,本申请中药组合物全方共66g),配伍更精炼。进一步,发明者发现本申请中药组合物临床能有效治疗膝骨关节炎发作期风湿热痹者,动物实验也研究证明其具有消肿作用,改善膝关节炎关节功能,并减轻膝关节软骨退变和滑膜炎症程度,有效治疗膝骨关节炎合并滑膜炎,且疗效优于健脾祛湿方和壮骨关节丸。
发明内容
为了解决现有技术问题,本发明提供一种配制简便、成本低、疗效显著、无副作用的治疗骨关节炎的中药组合物。
为了实现本发明的目的,本发明提供了一种治疗骨关节炎的中药组合物,所述中药组合物由如下重量份的原料药制成:茯苓10-20份、桂枝5-15 份、苍术2-8份 、黄柏2-8份、防己2-8份、猪苓2-8 份、骨碎补2-8份、延胡索5-15份、川牛膝3-9份。
优选地,所述中药组合物由如下重量份的原料药制成:茯苓12-18份、桂枝7-13份、苍术3-7份、黄柏3-7份、防己3-7份、猪苓3-7 份、骨碎补3-7份、延胡索8-12份、川牛膝4-8份。
更为优选地,所述中药组合物由如下重量份的原料药制成:茯苓15份、桂枝10 份、苍术5 份、黄柏5 份、防己5 份、猪苓5 份、骨碎补5份、延胡索10份、川牛膝6份。
本发明还提供了含有前述中药组合物的制剂,所述制剂为口服制剂。所述制剂由中药组合物与药学上可接受的载体组成,剂型选自水煎剂、丸剂、胶囊剂、颗粒剂、冲剂和口服液。
作为优选,所述制剂为水煎剂。
所述水煎剂的制备方法为:将原料药加5~7倍质量的水,浸泡1~1.5小时,然后煎煮30分钟,过滤;药渣再加3~5倍质量的水,煎煮20分钟,过滤;合并两次滤液,即得。
作为优选,将原料药加5倍质量的水,浸泡1.5小时,然后煎煮30分钟,过滤;药渣再加3倍质量的水,煎煮20分钟,过滤;合并两次滤液,即得。
本发明还提供了前述中药组合物在制备治疗膝骨关节炎尤其是发作期膝骨关节炎药物中的应用。
在本发明的中药组合物中:
茯苓:甘淡性平,归心、脾、肾经,有利水消肿、健脾渗湿之功效。
桂枝:辛甘性温,归肺、心、膀胱经,发汗解肌、温通经脉、助阳化气。
苍术:味辛苦性温,归脾、胃、肝经,燥湿健脾;祛风湿;明目。
黄柏:苦、寒,归肾经、膀胱、大肠经,清热解毒燥湿
防己:苦辛寒,入膀胱、肺、脾经,利水消肿,祛风除湿,散痈肿。
猪苓:甘淡性平,归肾、膀胱经,有利水消肿、渗湿之功效。
骨碎补:味苦性温,入肝、肾经,补肾强骨,续伤止痛
延胡索:辛苦温,归肝、胃、心、肺、脾经,活血散瘀、理气止痛。
川牛膝:味甘微苦性平,归肝、肾经,逐瘀通经、通利关节、利尿通淋。
其中,君药茯苓、桂枝健脾利湿、助阳化气、祛风通络;苍术、黄柏共为臣药,合奏健脾燥湿、祛风清热之效;佐以防己、猪苓、骨碎补、延胡索祛风清热、利水消肿;使以川牛膝滋补肝肾、活血止痛、引药下行直达病所。诸药合用,共奏健脾渗湿,清热利水,通络止痛之功。
本发明的有益效果在于:本发明所述的中药组合物,根据中医学“脾虚湿注”的理论和本发明人提出的发作期骨关节炎“脾虚水泛,湿注骨节,湿热痹阻”病机观点,以及现代中医理论,经过大量配伍研究得到。所述中药组合物具有健脾渗湿、清热利水、通络止痛等功效,通过临床试验进行验证,证明其对缓解发作期骨性关节炎患者疼痛、肿胀症状,改善膝关节功能,提高患者生存质量,延缓骨关节炎的病情发展具有显著效果,且毒副作用小,动物实验证明其能减轻膝骨关节炎关节肿胀、皮温升高等症状,改善关节功能,并减轻软骨退变和滑膜炎症程度,有效治疗膝骨关节炎合并滑膜炎,且疗效优于健脾祛湿方和壮骨关节丸,提示其对于发作期膝骨关节炎效果尤佳,且无明显毒副作用、价格低廉。
附图说明
图1所示为中药组合物对兔膝骨关节炎膝关节皮温、关节周径及Lequesne评分的影响。注:与正常组比较,###P<0.001;与模型组比较,*P<0.05,**P <0.01,***P <0.001。
图2所示为中药组合物对兔膝骨关节炎软骨表面墨汁着色情况的影响。
图3所示为中药组合物对骨关节炎兔关节软骨表面损伤分级评分的影响。注:与正常组比较,###P<0.001;与模型组比较,*P<0.05,**P <0.01,***P <0.001。
图4所示为中药组合物对膝骨关节炎兔关节软骨和滑膜组织学改变积分的影响。注:与正常组比较,###P<0.001;与模型组比较,*P<0.05,**P <0.01,***P <0.001。
图5所示为中药组合物对膝骨关节炎兔关节液中IL-1β、TNFα、PGE2、NO含量的影响。注:与正常组比较,###P<0.001;与模型组比较,*P<0.05,**P <0.01,***P <0.001。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例 1
取茯苓15g,桂枝10g,苍术5g,黄柏5g,防己5g,猪苓5g,骨碎补5g,延胡索10g,川牛膝6g,混合,向原料药中加5倍质量的水,浸泡1.5小时后,煎煮30分钟,过滤;药渣再加3倍质量的水,煎煮20分钟,过滤;合并两次滤液,制成水煎剂。
实施例 2
取茯苓10g,桂枝5g,苍术3g,黄柏3g,防己2g,猪苓2g,骨碎补2g,延胡索5g,川牛膝3g,混合,向原料药中加7倍质量的水,浸泡1小时后,煎煮30分钟,过滤;药渣再加5倍质量的水,煎煮20分钟,过滤;合并两次滤液,制成水煎剂。
实施例3
取茯苓11g,桂枝13g,苍术7g,黄柏7g,防己3,猪苓3g,骨碎补7g,延胡索12g,川牛膝4g,混合,向原料药中加6倍质量的水,浸泡1.2小时后,煎煮30分钟,过滤;药渣再加4倍质量的水,煎煮20分钟,过滤;合并两次滤液,制成水煎剂。
实施例 4
1、取茯苓18g,桂枝7g,苍术3g,黄柏3g,防己7g,猪苓7g,骨碎补2g,延胡索8g,川牛膝8g,混合,烘干,研磨粉碎,过100目筛,混匀。
2、每100g细粉用炼蜜约40g与适量水(炼蜜:水=1:2.5~3.0),以炼蜜为黏合剂,制成蜜丸;或以水或黄酒、醋为黏合剂,泛制法制成水丸剂。
实施例5
1、取茯苓15g,桂枝10g,苍术8g,黄柏8g,防己8g,猪苓8g,骨碎补8g,延胡索5g,川牛膝5g,混合,烘干,研磨粉碎。
2、水提取两次,第一次加10倍量水提取1h,滤过,药渣再加8倍量水提取1h,滤过,合并两次滤液。
3、减压浓缩至相对密度1.20~1.30,得水提液稠膏。
4、稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(可溶性淀粉、羧甲基纤维素钠、聚维酮)搅拌均匀,制得软材。
5、挤压过10目筛,得湿颗粒。
6、50~60℃干燥,干颗粒冷却后分别过10目筛和65目筛整粒,装胶囊,即得。
实施例6
1、取茯苓10g,桂枝8g,苍术8g,黄柏3g,防己6g,猪苓8g,骨碎补8g,延胡索5g,川牛膝6g,混合,烘干,研磨粉碎。
2、水提取两次,第一次加10倍量水提取1h,滤过,药渣再加8倍量水提取1h,滤过,合并两次滤液。
3、减压浓缩至相对密度1.20~1.30,得水提液稠膏。
4、稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(可溶性淀粉、羧甲基纤维素钠、聚维酮)搅拌均匀,制得制得软材。
5、挤压过10目筛,得湿颗粒。
6、50~60℃干燥,干颗粒冷却后分别过10目筛和65目筛整粒,即得。
实施例7
1、取茯苓10g,桂枝15g,苍术2g,黄柏2g,防己4g,猪苓3g,骨碎补5g,延胡索15g,川牛膝8g,混合,烘干,研磨粉碎。
2、水提取两次,第一次加10倍量水提取1h,滤过,药渣再加8倍量水提取1h,滤过,合并两次滤液。
3、减压浓缩至相对密度1.20~1.30,得水提液稠膏。
4、稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(可溶性淀粉、羧甲基纤维素钠、聚维酮)搅拌均匀,制得制得软材。
5、挤压过10目筛,得湿颗粒。
6、50~60℃干燥,干颗粒冷却后分别过10目筛和65目筛整粒,制成粉剂或颗粒状冲剂。
试验例1 治疗骨关节炎的中药组合物对家兔膝骨关节炎合并滑膜炎的治疗效果
1. 实验动物和试剂
1.1 动物 大耳白兔, 雌雄各半, 清洁级, 体重2.0-2.5kg, 北京金牧阳实验动物养殖有限责任公司提供,实验动物合格证许可证号:SCXK(京)2015-0005。
1.2 药物和试剂 本申请中药组合物(茯苓15g,桂枝10g,苍术5g,黄柏5g,防己5g,猪苓5g,骨碎补5g,延胡索10g,川牛膝6g)和健脾祛湿方(茯苓15g、猪苓10g、泽泻10g、炒白术10g、车前子10g、黄柏6g、党参10g、茵陈蒿10g、威灵仙10g和海桐皮10g)均购于北京同仁堂制药有限公司;壮骨关节丸:三九医药股份有限公司产品, 批号1512007s;木瓜蛋白酶,MERCK 公司产品, 批号F1343144506;; IL-1β、TNFα、PGE2和NO ELISA试剂盒:均为上海西唐生物有限公司产品。
1.3 仪器 AS325 切片机:德国SHANDON公司产品;自动脱水机、展片机、烤片机、包埋机、自动磨刀机:均为天津航空机电公司产品;BH-2 光学显微镜:日本Olympus;7200 分光光度计:UNICO 公司产品。
1.4 分组与给药 取大耳白兔40只, 按体重随机分6组, 每组8只, 即:正常组、模型组、本申请中药组合物治疗组(为3.3g/kg 生药),壮骨关节丸阳性对照组(1.1g/kg 药丸) , 健脾祛湿方对照组(为5.0g/kg 生药)。造模同时按5mL/kg 体重灌胃给药, 每天1次, 共6周, 正常组和模型组给予等容积蒸馏水。
1.5 造模 健康大耳白兔正常饲养1周后,将兔(正常组除外) 左后膝关节腔内注入1.6%木瓜蛋白酶生理盐水溶液0.5mL, 隔3d, 注射第2 次, 共注射2 次,建立膝兔骨关节炎模型。
1.6 局部皮温、关节周径的测量 分别于造模前后、灌胃后测量膝关节皮温及膝关节周径。膝关节皮温:使用红外测温仪测量局部温度,由同一个实验员操作并报数,重复测量3 次,取平均值。膝关节周径:用卷尺测量膝关节周径,由同一个实验员操作并读数,每个膝关节测量三次,并计算平均值。
1.7 动物行为学评分:对实验动物进行行为学评分,一方面可作为模型鉴定的补充,另一方面是作为对治疗后功能恢复的评价指标。本次实验采用Lequesne评分。分别于造模前和取材前,对各实验兔膝关节分别进行Lequesne 评估,从局部疼痛刺激反应、步态、关节活动范围、关节肿胀三个方面评估膝关节功能。评分见附录1。
附录1 Lequesne评分
1.局部疼痛刺激反应:用手指或棉签接触或挤压患处,按刺激反应程度不同分为4级:
2.步态:按患肢行走、奔跑时的步态分为4级:
3.关节活动范围:按患肢膝关节活动范围分为4级(伸直为0°):
4.关节肿胀:按膝关节肿胀程度分为3级:
Ⅰ级:无肿胀,骨性标记清楚可见。 | 0分 |
Ⅱ级:轻度肿胀,骨性标记变浅。 | 1分 |
Ⅲ级:骨性标记消失。 | 2分 |
1.6 组织取材与处理 造模6周后,麻醉后取关节液将膝关节逐层分离至肌肉,以髌骨上缘为定位,行髌骨上缘横向切口,行肉眼观察关节内情况,包括关节液颜色及量,用有齿镊夹住髌骨轻轻向上提拉,分别沿膝关节内侧、外侧作纵行切口至股骨髁上方,屈曲兔膝关节,助手轻轻挤压膝关节内外侧,使关节液集中在胫骨平台周围方便抽取。用注射器抽取关节液后存入EP 管中,迅速投入液氮中保存,留用于ELISA检测。打开关节腔, 肉眼观察关节软骨和滑膜表面情况, 并在关节表面滴印度墨汁,然后用生理盐水湿过的棉签轻擦关节表面, 肉眼观察关节表面墨汁着色情况并进行软骨损伤计分。分离取出膝关节前正中部分的滑膜组织,作HE 染色,光镜下观察。取左侧股骨下端及胫骨上端进行组织病理病理学检查,光镜下观察。
1.7 ELISA检测:测定关节液中IL-1β、TNFα、PGE2、NO含量,采用ELISA法, 操作步骤参照试剂盒说明。
1.8 评估标准 观察关节软骨墨汁着色情况并进行软骨损伤分级。0分:正常, 关节面完整光滑,无墨汁残留;1分:轻度纤维化, 未滴墨汁前肉眼见关节面正常, 滴墨汁后关节表面留下浅灰色斑点;2分:明显纤维化, 关节面不光滑, 无光泽, 滴墨汁后关节表面留下深黑色墨汁色斑片;3分:软骨糜烂, 部分软骨丢失, 软骨下骨暴露, 滴墨汁后关节表面留下深黑色的墨汁色斑块。按Mankin 骨关节病组织学分类方法对软骨及滑膜进行组织病理评分,分级标准:正常0-2分,轻度病变2-7分,中度病变8-11分,重度病变12-14分。模型鉴定结果:软骨Mankins评分约4.5分,滑膜HE染色可见表层增生显著,炎性细胞浸润,血管增生,充血,提示造模成功。
1.9 统计学方法 实验数据以均数±标准差(±s) 表示, 采用SPSS 15.0 软件对其进行统计,肉眼和光镜观察关节软骨和滑膜病变情况, 采用单因素多组资料的H 检验和q 检验, IL-1β、TNFα、PGE2和NO含量。
采用单因素方差分析
2. 结果
2.1 中药组合物对兔膝骨关节炎膝关节皮温、关节周径及Lequesne评分的影响
如图1所示,与正常组比较,模型组关节局部皮温、关节周径和Lequesne评分均显著升高(P <0.001);与模型组比较,中药组合物、健脾祛湿方干预后均能显著降低关节局部皮温、关节周径和Lequesne评分,壮骨关节丸也能明显降低Lequesne评分,但对关节局部皮温、关节周径没有明显影响。提示中药组合物能减轻膝骨关节炎兔关节肿胀、皮温升高等症状,改善关节功能,其作用与健脾祛湿方接近,但优于壮骨关节丸。
2.1 中药组合物对膝骨关节炎兔软骨和滑膜病变的影响
2.1.1 大体观察 各组实验兔(正常组除外)在左膝关节腔内注入木瓜蛋白酶后,关节出现轻微肿胀, 活动减少, 约1周后肿胀消失, 活动基本恢复正常。打开关节腔, 肉眼观察见正常组关节软骨表面光滑呈淡蓝色;模型组关节软骨表面呈黄色;中药组合物组、健脾祛湿方、壮骨关节丸组关节软骨颜色淡白。模型组滑膜较正常组肥厚、充血;中药组合物组、健脾祛湿方、壮骨关节丸组滑膜较正常组略有增厚,但不及模型组严重。
2.1.2 根据软骨表面墨汁着色情况肉眼观察软骨损伤分级积分结果 如图2和图3显示,正常组软骨表面基本正常;模型组软骨表面损伤明显, 与正常组比较差异显著(P<0.001);与模型组比较,中药组合物组、对照组健脾祛湿方和壮骨关节丸均不同程度地减轻软骨表面损伤程度,且中药组合物作用最明显(P<0. 01)。
2.1.3 HE 染色观察软骨和滑膜组织学改变积分结果 关节腔内注射木瓜蛋白酶可使关节软骨出现明显退行性病变, 软骨表面有明显缺损, 甚至骨质破坏, 缺损表面可见纤维结缔组织增生和新生的毛细血管即血管翳形成, 软骨基质变性, 软骨细胞消失,软骨层变薄;滑膜细胞增生且排列不规则, 炎性细胞大量浸润, 其下可见大量结缔组织,模型组与正常组比较病变严重;与模型组相比,中药组合物、健脾祛湿方和壮骨关节丸对照组病变明显减轻,且中药组合物作用最明显(P <0.01),见图4。
2.2 中药组合物对膝骨关节炎兔关节液中IL-1β、TNFα、PGE2、NO含量的影响
如图5所示,与正常组比较,模型组关节液中IL-1β、TNFα、PGE2、NO含量均显著升高;与模型组比较,中药组合物、健脾祛湿方和壮骨关节丸组关节液中IL-1β、TNFα、PGE2、NO含量均降低,且中药组合物作用最明显(P<0.001)、健脾祛湿方作用次之(P <0.01)。
总结
用本发明中药组合物对发作期膝骨关节炎兔进行干预,结果显示其能减轻膝骨关节炎兔关节肿胀、皮温升高等症状,改善兔膝关节功能,并通过降低关节内IL-1β、TNFα、PGE2、NO的表达,减轻滑膜炎症,延缓膝骨关节炎进展,且其作用优于健脾祛湿方和壮骨关节丸。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (9)
1.一种治疗发作期骨关节炎的中药组合物,其特征在于,所述中药组合物由如下重量份的原料药制成:茯苓10-20份、桂枝5-15份、苍术2-8份、黄柏2-8份、防己2-8份、猪苓2-8份、骨碎补2-8份、延胡索5-15份、川牛膝3-9份。
2.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物由如下重量份的原料药制成:茯苓12-18份、桂枝7-13份、苍术3-7份、黄柏3-7份、防己3-7份、猪苓3-7份、骨碎补3-7份、延胡索8-12份、川牛膝4-8份。
3.根据权利要求2所述的中药组合物,其特征在于,所述中药组合物由如下重量份的原料药制成:茯苓15份、桂枝10份、苍术5份、黄柏5份、防己5份、猪苓5份、骨碎补5份、延胡索10份、川牛膝6份。
4.含权利要求1-3任一项所述的中药组合物的制剂,其特征在于,所述制剂为口服制剂。
5.根据权利要求4所述的制剂,其特征在于,所述制剂由中药组合物与药学上可接受的载体组成,剂型选自水煎剂、丸剂、胶囊剂、颗粒剂、冲剂和口服液。
6.根据权利要求5所述的制剂,其特征在于,所述制剂为水煎剂。
7.根据权利要求6所述的制剂,其特征在于,所述水煎剂的制备方法为:将原料药加5~7倍质量的水,浸泡1~1.5小时,然后煎煮30分钟,过滤;药渣再加3~5倍质量的水,煎煮20分钟,过滤;合并两次滤液,即得。
8.根据权利要求7所述的制剂,其特征在于,所述水煎剂的制备方法为:将原料药加5倍质量的水,浸泡1.5小时,然后煎煮30分钟,过滤;药渣再加3倍质量的水,煎煮20分钟,过滤;合并两次滤液,即得。
9.权利要求1-3任一项所述的中药组合物在制备治疗发作期骨关节炎和膝骨关节炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010096924.1A CN111184792B (zh) | 2020-02-17 | 2020-02-17 | 一种治疗膝骨关节炎的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010096924.1A CN111184792B (zh) | 2020-02-17 | 2020-02-17 | 一种治疗膝骨关节炎的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111184792A CN111184792A (zh) | 2020-05-22 |
CN111184792B true CN111184792B (zh) | 2022-05-06 |
Family
ID=70687333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010096924.1A Active CN111184792B (zh) | 2020-02-17 | 2020-02-17 | 一种治疗膝骨关节炎的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111184792B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113876859B (zh) * | 2021-11-16 | 2023-03-14 | 河南省人民医院 | 一种治疗骨关节活动障碍的外用中药组合物 |
CN114908038B (zh) * | 2022-06-06 | 2024-03-15 | 苏州大学 | 一种体外3d关节损伤模型及其构建与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899436A (zh) * | 2005-07-22 | 2007-01-24 | 曹月龙 | 一种中药复方制剂的制备方法和用途 |
CN101926905B (zh) * | 2010-07-14 | 2011-09-14 | 陈卫衡 | 含健脾化痰成分的中药组合物在制备治疗早中期股骨头坏死的药物中的用途 |
CN103169822B (zh) * | 2013-04-17 | 2015-05-27 | 宁夏张氏回医正骨医院 | 滑膜炎回药膏及其制备方法 |
CN104225112B (zh) * | 2013-06-13 | 2017-12-22 | 陈卫衡 | 一种治疗骨性关节炎的中药组合物 |
CN105853526A (zh) * | 2016-06-03 | 2016-08-17 | 王惠杰 | 用于治疗关节腔积液的中药散剂及其制备方法、应用 |
-
2020
- 2020-02-17 CN CN202010096924.1A patent/CN111184792B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111184792A (zh) | 2020-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102847063B (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
CN111184792B (zh) | 一种治疗膝骨关节炎的中药组合物 | |
CN103055239B (zh) | 养颜祛斑的中药及其制备方法 | |
CN101897821A (zh) | 一种活血通络止痛的颗粒剂及其制备和质量控制方法 | |
CN102988733A (zh) | 治疗产后缺乳的中药组合物及其制备方法 | |
CN101028325B (zh) | 一种含有塞隆骨的药物组合物及其制备方法和质量检测方法 | |
CN104524247A (zh) | 一种治疗偏头痛的药物组合物及其用途 | |
CN103908603B (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN108144038B (zh) | 一种祛除黄褐斑的中药组合物及其应用 | |
CN105194427A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
CN104491344A (zh) | 一种中药制剂在制备治疗眼目暴赤肿痛药物中的用途 | |
CN104324139B (zh) | 一种治疗干眼症的药物组合物 | |
CN114344422B (zh) | 一种防治术后气血亏虚肠燥证便秘的中药组合物及其应用 | |
CN103301373A (zh) | 一种治疗产后会阴粘膜病变的药物组合物 | |
CN104771529A (zh) | 一种治疗肝肾亏虚型创伤性关节炎的药物及制备方法 | |
CN109419844B (zh) | 一种治疗骨关节炎疼痛的藏药组合物 | |
CN105456657A (zh) | 治疗女性绝经后骨质疏松症的中药组合物及其制备方法 | |
CN103948837A (zh) | 治疗湿热痹阻所致痛风的中药组合物及其制备方法 | |
CN105395914A (zh) | 一种治疗膀胱结石的中药组合物及其制备方法和用途 | |
CN116808128A (zh) | 一种治疗膝骨关节炎的中药组合物及其制备方法和应用 | |
CN104189365B (zh) | 治疗人体疼痛的中药组合物及其制剂和制法 | |
CN113318167A (zh) | 一种治疗类风湿性关节炎的中药组合物 | |
CN105749044A (zh) | 一种治疗慢性肾炎的中药制剂 | |
CN105963493A (zh) | 一种治疗跟痛症的中药组合物及其制备方法 | |
CN105770600A (zh) | 一种中药制剂在制备治疗慢性肾炎的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231207 Address after: Room 708, 125/F, Wangjing Garden, Chaoyang District, Beijing, 100102 Patentee after: Chen Weiheng Address before: 100102 1001, unit 1, building 10, donghuwan West District, West 2nd Street, Lize, Wangjing, Chaoyang District, Beijing Patentee before: Chen Weiheng Patentee before: Lin Na |
|
TR01 | Transfer of patent right |